

Instructions for Authors 2018

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis. The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

Open Access Policy. IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 575.00 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 58.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear **at the end** of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

Tables. All tables should appear **at the end** of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC -IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

Ethical Policies and Standards. IN VIVO agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors


1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.

4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
5. Authors should pay attention to the following points when writing an article for IN VIVO:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
8. Articles submitted to IN VIVO may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to IV.
 - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 59%).
9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org.
11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).

Copyright© 2018 – International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

ISSN (online): 1790-6245



Published by the International Institute of Anticancer Research

Online ISSN: 1790-6245

General Policy

- **CANCER GENOMICS & PROTEOMICS (CGP)** welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.
- CGP is published bimonthly by the **International Institute of Anticancer Research (IIAR)** and is available online only and open access with **Stanford University HighWire Press**. The IIAR is a member of UICC. For more information please visit our website www.cgp.iiarjournals.org.
- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.
U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.
- **E-mail:** journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

● Selection of Recent Articles

The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. U.H. WEIDLE, S. DICKOPF, C. HINTERMAIR, G. KOLLMORGEN, F. BIRZELE, U. BRINKMANN (*Penzberg; Munich, Germany; Basel, Switzerland*)

Transcriptomic Profiling of MDA-MB-231 Cells Exposed to *Boswellia Serrata* and 3-O-Acetyl-B-Boswellic Acid; ER/UPR Mediated Programmed Cell Death. M.A. ELIZABETH, L.A. CHARLES, SOLIMAN F.A. KARAM (*Tallahassee, FL, USA*)

Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer. L. BASSARO, S.J. RUSSELL, E. PASTWA, S.A. SOMIARI, R.I. SOMIARI (*Johnstown; Windber, PA, USA*)

DHPLC elution Patterns of VDR PCR Products Can Predict Prostate Cancer Susceptibility in African American Men. R.L. COPELAND, D. BEYENE, V. APPREY, M.R. DAREMPOURAN, T.J. NAAB, O.O. KASSIM, Y.M. KANAAN (*Washington, DC, USA*)

Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL Derived Cell Line CPT-K5. E. KJELDSEN, C.J.F. NIELSEN, A. ROY, C. TESAURO, A.-K. JAKOBSEN, M. STOUGAARD, B.R. KNUDSEN (*Aarhus, Denmark*)

Regulation of β -Catenin Phosphorylation by PR55 β in Adenoid Cystic Carcinoma. K. ISHIBASHI, K. ISHII, G. SUGIYAMA, Y. KAMATA, A. SUZUKI, W. KUMAMARU, Y. OHYAMA, H. NAKANO, T. KIYOSHIMA, T. SUMIDA, T. YAMADA, Y. MORI (*Fukuoka, Japan*)

Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans. B.D. WILSON, L.J. RICKS-SANTI, T.E. MASON, M. ABBAS, R.A. KITTLES, G.M. DUNSTON, Y.M. KANAAN (*Washington, DC; Hampton, VA; Duarte, CA, USA*)

Consistent Involvement of Chromosome 13 in Angiolipoma. I. PANAGOPOULOS, L. GORUNOVA, K. ANDERSEN, I. LOBMAIER, B. BJERKEHAGEN, S. HEIM (*Oslo, Norway*)

Analysis of K-Ras Interactions by Biotin Ligase Tagging. C. RITCHIE, A. MACK, L. HARPER, A. ALFADHLI, P.J.S. STORK, X. NAN, E. BARKLIS (*Portland, OR, USA*)

CYP3A4 Gene Is a Novel Biomarker for Predicting a Poor Prognosis in Hepatocellular Carcinoma. R. ASHIDA, Y. OKAMURA, K. OHSHIMA, Y. KAKUDA, K. UESAKA, T. SUGIURA, T. ITO, Y. YAMAMOTO, T. SUGINO, K. URAKAMI, M. KUSUHARA, K. YAMAGUCHI (*Shizuoka; Tokyo, Japan*)

Contents

Reviews

Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. A. NOGUEIRA, M.J. PIRES, P.A. OLIVEIRA (<i>Vila Real, Braga, Portugal</i>)	1
Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review. C. PERISANIDIS (<i>Vienna, Austria</i>)	23
Clinical Factors Associated with Treatment Outcomes Following Whole-brain Irradiation in Patients with Prostate Cancer. L. DZIGGEL, S.E. SCHILD, T. VENINGA, A. BAJROVIC, D. RADES (<i>Lübeck, Hamburg, Germany; Scottsdale, AZ, USA; Tilburg, the Netherlands</i>)	35
Experimental Studies	
Effectiveness of Analogs of the GS-Nitroside, JP4-039, as Total Body Irradiation Mitigators. M.W. EPPERLY, J.R. SACHER, T. HRANIZ, X. ZHANG, P. WIPP, M. LIANG, R. FISHER, S. LI, H. WANG, J.S. GREENBERGER (<i>Pittsburgh, PA, USA</i>)	39
Active and Passive Immunization Against <i>Staphylococcus aureus</i> Periprosthetic Osteomyelitis in Rats. N.H.SØE, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (<i>Hallerup, Copenhagen; Hørsholm, Denmark; Boston, MA, USA</i>)	45
Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd:YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKOSE, H. SAKAGAMI (<i>Saitama, Japan</i>)	51
Wound Healing Delay in the ZSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (<i>St. Paul, MN; Indianapolis, IN, USA</i>)	55
Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells. Y. MURAMATSU, T. MATSUI, M. DEIE, K. SATO (<i>Aichi, Japan</i>)	61

Content continued on the back cover

ISSN (online): 1791-7549

General Policy

- **IN VIVO** is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.
- The principal aim of **IN VIVO** is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.
- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

- **E-mail:** journals@iia-anticancer.org; IIA WEBSITES: www.iia-anticancer.org and www.iiajournals.org

- **International Journal of Experimental and Clinical Pathophysiology and Drug Research**
- **Published bimonthly by the International Institute of Anticancer Research**
- **Available online only and open access with Stanford University HighWire Press**

● Selection of Recent Articles

Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer. S.M. GLASER, R. KALASH, D.R. BONGIORNI, M.S. ROBERTS, G.K. BALASUBRAMANI, B.L. JACOBS, S. BERIWAL, D.E. HERON, J.S. GREENBERGER (*Duarte, CA; Pittsburgh, PA, USA*)

Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers. S.A. ERICH, F. CONSTANTINO-CASAS, J.M. DOBSON, E. TESKE (*Utrecht, The Netherlands; Cambridge, UK*)

Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts. R.A. VAN NOORD, T. THOMAS, M. KROOK, S. CHUKKAPALLI, M.J. HOENERHOFF, J.R. DILLMAN, E.R. LAWLOR, V.P. OPIPARI, E.A. NEWMAN (*Ann Arbor, MI, USA*)

Re-evaluation of Culture Condition of PC12 and SH-SY5Y Cells Based on Growth Rate and Amino Acid Consumption. H. SAKAGAMI, R. SUZUKI, Y. SHIRATAKI, S. IWAMA, M. NAKAGAWA, H. SUZUKI, K. TANAKA, N. TAMURA, H. TAKESHIMA (*Sakado, Japan*)

Clinical Impact of Rest Dual-Energy Computed Tomography Myocardial Perfusion in Patients with Coronary Artery Disease. S. BAUMANN, *et al.* (*Mannheim, Germany*)

Effects of 2,3-Bis(4-hydroxyphenyl)-propionitrile on Induction of Polyovular Follicles in the Mouse Ovary. T. SATO, H. KIM, H. KAKUTA, T. IGUCHI (*Yokohama, Japan*)

Cell-cycle Checkpoints and Aneuploidy on the Path to Cancer. E.S. WENZEL, A.T.K. SINGH (*Kenosha, WI, USA*)

The Association of MMP-8 Genotypes with Pterygium. P.-S. HU, W.-S. CHANG, A.-K. CHOU, N.-Y. HSIA, Y.-W. HUNG, C.-W. LIN, C.-W. WU, C.-Y. HUANG, M.-F. WU, C.-H. LIAO, C.-W. TSAI, D.-T. BAU, C.-L. GONG (*Changhua; Taichung; Taoyuan, Taiwan, ROC*)

Profiling Neutrophil-to-Lymphocyte Ratio Changes in Response to Nucleoside Analog Therapy for Chronic Hepatitis B Infection. M. MARALLAG, A. PATEL, M. CHOI, M.N. WONG, A.B. SEETHARAM (*Phoenix; Tempe, AZ, USA*)

Comparison of the Grip Strength Using the Martin-Vigormeter and the JAMAR-Dynamometer: Establishment of Normal Values. S. NEUMANN, S. KWISDA, C. KRETTEK, R. GAULKE (*Hannover; Hamburg, Germany; Zurich, Switzerland*)

Role for Neutrophil Extracellular Traps (NETs) and Platelet Aggregation in Early Sepsis-induced Hepatic Dysfunction. K. SAKURAI, T. MIYASHITA, *et al.* (*Ishikawa, Japan; Baltimore, MD, USA*)

Netrin-4 Promotes Differentiation and Migration of Osteoblasts. Y. ENOKI, T. SATO, S. KOKABU, N. HAYASHI, T. IWATA, M. YAMATO, M. USUI, M. MATSUMOTO, T. TOMODA, W. ARIYOSHI, T. NISHIHARA, T. YODA (*Saitama; Fukuoka; Tokyo, Japan*)

Early PET-CT After Stereotactic Radiotherapy for Stage I Non-small-cell Lung Carcinoma Is Predictive of Local Control. M. TYRAN, N. CHARRIER, J. DARREON, A. MADROSZYK, A. TALLET, N. SALEM (*Marseille, France*)

Plasma Electrolytic Oxidation of Titanium Implant Surfaces: Microgroove-Structures Improve Cellular Adhesion and Viability. P. HARTJEN, A. HOFFMANN, A. HENNINGSSEN, M. BARBECK, A. KOPP, L. KLUWE, C. PRECHT, O. QUATELA, R. GAUDIN, M. HEILAND, R.E. FRIEDRICH, D. GRUBEANU, R. SMEETS, O. JUNG (*Hamburg-Eppendorf; Idstein; Berlin; Aachen, Germany*)

High-risk Stage II Colorectal Cancers Carry an Equivalent Risk of Peritoneal Recurrence to Stage III. H. NOZAWA, K. KAWAI, K. HATA, T. TANAKA, T. NISHIKAWA, K. OTANI, K. SASAKI, M. KANEKO, S. EMOTO, K. MURONO (<i>Tokyo, Japan</i>)	1235
An Adult Patient with Early Pre-B Acute Lymphoblastic Leukemia with t(12;17)(p13;q21)/ZNF384-TAF15. N. GEORGAKOPOULOS, P. DIAMANTOPOULOS, F. MICCI, N. GIANNAKOPOULOU, K. ZERVAKIS, A. DIMITRAKOPOULOU, N.-A. VINIOU (<i>Athens, Greece; Oslo, Norway</i>)	1241
The Impact on the Long-term Outcomes of Hormonal Status After Hepatic Resection for Breast Cancer Liver Metastases. N. BACALBASA, I. BADESCU, V. ILIE, R. FLOREA, A. SOROP, V. BRASOVEANU, I. BREZEAN, M. VILCU, S. DIMA, I. POPESCU (<i>Bucharest, Romania</i>)	1247
Prevalence of HSV1/2 Congenital Infection Assessed Through Genome Detection on Dried Blood Spot in Individuals with Autism Spectrum Disorders. E. ZAPPULO, M.P. RICCIO, S. BINDA, L. PELLEGRINELLI, F. PREGLIASCO, A.R. BUONOMO, B. PINCHERA, G. D'URSO, C. BRAVACCIO, G. BORGIA, I. GENTILE (<i>Naples; Milan, Italy</i>)	1255
Transcutaneous Carbon Dioxide Treatment Affects Heart Rate Variability – A Pilot Study. Z. KRESKA, B. NÉMETH, I. KISS, I. PÉTER, Z. AJTAY, L. HEJJEL (<i>Harkány; Pécs, Hungary</i>).....	1259
Refractive Nightmares Revisited: Calcification of a Multifocal Intraocular Lens. M.M. MOSCHOS, K. LAIOS, A. LAVARIS, C. DAMASKOS, N. GARMPI, A. THABIT, D. LAKE, S. HAMADA, A. GARMPI, Z. GATZIOUFAS (<i>Athens, Greece; East Grinstead, UK</i>).....	1265
The Importance of Concurrent Chemotherapy for T1 Esophageal Cancer: Role of FDG-PET/CT for Local Control. I. OGINO, S. WATANABE, K. HIRASAWA, T. MISUMI, M. HATA, C. KUNISAKI (<i>Yokohama, Japan</i>).....	1269
Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients. A. EL-BALAT, I. SCHMEIL, T. KARN, U. HOLTRICH, L. MAVROVA-RISTESKA, A. RODY, A. YOUSSEF, L.C. HANKER (<i>Frankfurt; Lübeck, Germany; Bologna, Italy</i>).....	1275
Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer. A.C. LOHMAN, I. VAN RIJN, C.L. LINDHARDT, R. VONTHEIN, D. RADES, N.H. HOLLÄNDER (<i>Naestved; Kolding; Sorø, Denmark; Lübeck, Germany</i>).....	1283

Clinical Studies

Cellular Phone Irradiation of the Head Affects Heart Rate Variability Depending on Inspiration/Expiration Ratio. S. BIRES, A. NIMETH, Z. AJTAY, I. KISS, B. NIMETH, L. HEJJEL (<i>Pécs, Hungary</i>).....	1145
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small Cell Lung Cancer: Phase II Study. K. YAMAGUCHI, T. MASUDA, K. FUJITAKA, K. MIWATA, S. SAKAMOTO, Y. HORIMASU, K. HAMAI, S. MIYAMOTO, T. NAKASHIMA, Y. OKAMOTO, H. IWAMOTO, N. ISHIKAWA, Y. MIYATA, M. OKADA, H. HAMADA, N. HATTORI (<i>Hiroshima, Japan</i>).....	1155
Standardized Screening and Psycho-oncological Treatment of Orthopedic Cancer Patients. F. LENZE, C. KIRCHHOFF, F. POHLIG, C. KNEBEL, H. RECHL, B. MARTEN-MITTAG, P. HERSCHBACH, R.V. EISENHART-ROTHE, U. LENZE (<i>Munich, Germany</i>).....	1161
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma. Y. NEGI, K. KURIBAYASHI, N. FUNAGUCHI, H. DOI, K. MIKAMI, T. MINAMI, T. TAKUWA, T. YOKOI, S. HASEGAWA, T. KIJIMA (<i>Hyogo, Japan</i>).....	1169
EGF Level in Hepatoid Gland Adenomas and Hepatoid Gland Epitheliomas in Dogs After Administering Tamoxifen. A. SOBCZYŃSKA-RAK, B. ŻYLIŃSKA, Ł. JAROSZ, A. BRODZKI, M. TATARA (<i>Lublin, Poland</i>).....	1175
R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy. H. KAMACHI, Y. TSURUGA, T. ORIMO, K. WAKAYAMA, S. SHIMADA, A. NAGATSU, H. YOKOO, T. KAMIYAMA, N. KATOH, A. TAKETOMI (<i>Sapporo, Japan</i>).....	1183
Peak of Standardized Uptake Value in Oral Cancer Predicts Survival Adjusting for Pathological Stage. H. SUZUKI, T. TAMAKI, M. NISHIO, S. BEPPU, N. MUKOYAMA, N. HANAI, D. NISHIKAWA, Y. KOIDE, Y. HASEGAWA (<i>Nagoya, Japan</i>).....	1193
T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring EGFR Mutations. Y. KOGURE, F. SHIGEMATSU, M. OKI, H. SAKA (<i>Nagoya, Japan</i>).....	1199
A Case of a Pregnant Woman Diagnosed as Having ALK-rearranged Lung Adenocarcinoma. M. KOMURA, S. YAGISHITA, K. NAKAMURA, N. ARANO, T. TAKESHIGE, K. MURAKI, O. NAGASHIMA, H. IZUMI, S. TOMITA, S. SASAKI, K. TAKAHASHI (<i>Urayasu; Tokyo, Japan</i>).....	1205
Pathological Complete Response by S-1 Chemotherapy in Advanced Gastric Cancer. T. NAMIKAWA, N. ISHIDA, S. TSUDA, K. FUJISAWA, E. MUNEKAGE, J. IWABU, M. MUNEKAGE, S. UEMURA, S. TSUJII, H. MAEDA, H. KITAGAWA, M. KOBAYASHI, K. HANAZAKI (<i>Kochi, Japan</i>).....	1211
Reconstruction of Inferior Right Hepatic Veins in Living Donor Liver Transplantation. N. BACALBASA, I. BALESU, M. PAUTOV, J. BREZEAN, M. VILCU, V. BRASOVEANU (<i>Bucharest, Romania</i>).....	1217
Mechanical Thrombectomy of Large Artery Occlusion Is Beneficial in Octogenarians. S. KARHI, O. NERG, T. MIETTINEN, E. MÄKIPAAKKANEN, M. TAINA, H. MANNINEN, R. VANNINEN, P. JÄKÄLÄ (<i>Kuopio, Finland</i>).....	1223
Ovarian Teratoma or Uterine Malformation? PET/MRI as a Novel Useful Tool in NMDAR Encephalitis. F. CRIMÌ, G. CAMPORESE, C. LACOGNATA, G. FANELLI, D. CECCHIN, M. ZOCCARATO (<i>Padua, Italy</i>).....	1231

Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer. C.-H. LIAO, W.-S. CHANG, C.-W. TSAI, P.-S. HU, H.-C. WU, S.-W. HSU, G.-L. CHEN, T.-C. YUEH, T.-C. SHEN, T.-C. HSIA, D.-T. BAU (<i>Taichung; Taipei; Changhua, Taiwan, ROC</i>)	1045
Carcinogenic Pesticide Control via Hijacking Endosymbiosis; The Paradigm of DSB-A from <i>Wolbachia pipientis</i> for the Management of <i>Otiorhynchus singularis</i> . T. KOSTAROPOULOS, L. PAPAGEORGIOU, S. CHAMPERIS TSANIRAS, D. VLACHAKIS, E. ELIOPOULOS (<i>Athens; Patras, Greece; London, UK</i>)	1051
Interaction of a Potential Anticancer Agent Hypericin and its Model Compound Emodin with DNA and Bovine Serum Albumin. J. STANIČOVÁ, V. VEREBOVÁ, J. BENEŠ (<i>Košice, Slovakia; Prague, Czech Republic</i>)	1063
Characterisation of a Mouse Model of Breast Cancer with Metabolic Syndrome. L.A. BUSS, A. MANDANI, E. PHILLIPS, N.J.A. SCOTT, M.J. CURRIE, G.U. DACHS (<i>Christchurch, New Zealand</i>)	1071
Antitumor Activity of Betulinic Acid and Betulin in Canine Cancer Cell Lines. J. ZHAO, R. LI, A. PAWLAK, M. HENKLEWSKA, A. SYSAK, L. WEN, J.-E. YI, B. OBMIŃSKA-MRUKOWICZ (<i>Changsha, PR China; Wroclaw, Poland</i>)	1081
Fermented Lingonberry Juice Inhibits Oral Tongue Squamous Cell Carcinoma Invasion <i>In Vitro</i> Similarly to Curcumin. D. HOORNSTRA, J. VESTERLIN, P. PÄRNÄNEN, A. AL-SAMADI, A. ZLOTOGORSKI-HURVITZ, M. VERED, T. SALO (<i>Helsinki; Oulu, Finland; Tel Aviv; Tel Hashomer, Israel</i>)	1089
Amentoflavone Inhibits Hepatocellular Carcinoma Progression Through Blockage of ERK/NF-κB Activation. K.-C. LEE, W.-T. CHEN, Y.-C. LIU, S.-S. LIN, F.-T. HSU (<i>Taichung; Yilan; Kaohsiung; Taipei, Taiwan, ROC</i>)	1097
Endothelial Lipase Gene Polymorphism (584 C/T) in Coronary Artery Patients Among a Turkish Population. L.A. SOLIM, I.A. GENCAN, B. ÇELIK, A. ATAACAR, U. KOH, B. BÜYÜKÖREN, G. GÜNGÖR, S. ISBIR (<i>Istanbul, Turkey</i>)	1105
Vertical Bone Augmentation Using Three-dimensionally Printed Cap in the Rat Calvarial Partial Defect. J.-M. KIM, J.-H. KIM, B.-H. LEE, S.H. CHOI (<i>Seoul; Cheongju; Cheonan, Republic of Korea</i>)	1111
Lauryl Gallate Induces Apoptotic Cell Death through Caspase-dependent Pathway in U87 Human Glioblastoma Cells <i>In Vitro</i> . C.-C. LIU, W.-W. LIN, C.-C. WU, S.-L. HSU, C.-Y. WANG, J.-G. CHUNG, C.-S. CHIANG (<i>Hsinchu; Taichung, Taiwan, ROC</i>)	1119
Bufalin Enhances Immune Responses in Leukemic Mice Through Enhancing Phagocytosis of Macrophage <i>In Vivo</i> . Y.-L. SHIH, J.-S. CHOU, Y.-L. CHEN, S.-C. HSUEH, H.-Y. CHUNG, M.-H. LEE, C.-P. CHEN, M.-Z. LEE, H.-T. HOU, H.-F. LU, K.-W. CHEN, J.-G. CHUNG (<i>Taipei; New Taipei; Hsinchu; Houlong; Changhua; Taichung, Taiwan, ROC</i>)	1129
Antitumor Ability of KT2 Peptide Derived from Leukocyte Peptide of Crocodile Against Human HCT116 Colon Cancer Xenografts. P. MARAMING, S. MAIJAROEN, S. KLAYNONGSRUANG, P. BOONSIRI, S. DADUANG, J.-G. CHUNG, J. DADUANG (<i>Khon Kaen, Thailand; Taichung, Taiwan, ROC</i>)	1137